BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding ...
STAT21h
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
News Medical1d
Innovative vaccine shields livestock from four strains of foot and mouth disease
A new vaccine, designed to protect East African cattle against all major strains of foot and mouth disease, is offering hope to small-scale farmers battling the highly contagious disease. Foot and ...
Novavax, Inc.: Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...